Abstract: Natalizumab is a very effective, relatively new drug for the treatment of relapsing remitting multiple sclerosis. Inflammatory and neurodegenerative processes in the central nervous system are presumed to cause adverse effects during the course of this disease. To monitor the effects of natalizumab treatment on the cerebrospinal fluid (CSF) proteome of patients, CSF samples were taken from patients before commencing treatment as well as after 1 year of treatment. Profiling proteomics experiments using electrospray Orbitrap mass spectrometry and pair wise comparison of patients before and after 1 year of natalizumab treatment revealed a number of candidate biomarkers that were significantly differentially abundant between the before and after treatment groups. Three proteins were subsequently validated using selected reaction monitoring (SRM) in a new, independent sample set. All three proteins, Ig mu chain C region and haptoglobin, both known inflammation-related proteins, as well as Chitinase-3-like protein 1, were confirmed by SRM to be significantly lower abundant in CSF of multiple sclerosis patients after 1 year of natalizumab treatment. The findings for Chitinase-3-like protein 1, a presumed biomarker for more rapid progression from a first clinically isolated syndrome to clinically definite multiple sclerosis, was further confirmed by ELISA measurements.
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. RR MScl is characterized by relapses with increased disease activity, which occur at irregular intervals, followed by periods of remission. It is believed that the disease process starts with increased migration of auto-reactive lymphocytes across the blood-brain barrier 5 .
Treatment for RR MScl is focused on the reduction of the number of relapses. These therapeutic agents, such as interferon beta and glatiramer acetate, are only moderately effective and reduce the annualized relapse rate by about a third [6] [7] .
The monoclonal antibody natalizumab (brand name: Tysabri) is an effective agent in the prevention of clinical relapses in relapsing remitting multiple sclerosis patients, reducing the relapse rate by 68% 8 . The therapeutic effect of natalizumab is thought to be mediated by suppression of leukocyte migration into the central nervous system by blocking the Very-Late Activation Antigen 4 ligand on immune cells 9 . As a consequence, a reduction of inflammation and inflammatory mediators might be observable in the central nervous system of natalizumab treated patients. However, neurodegeneration-related proteins were recently also reported to be influenced by natalizumab treatment 10 .
In this study, we employed state-of-the-art quantitative proteomics techniques to differentiate between cerebrospinal fluid (CSF) samples of multiple sclerosis patients before and after treatment with natalizumab.
Methods
CSF samples were taken from relapsing remitting MScl patients before natalizumab treatment commenced at the University Medical Center Eppendorf (Hamburg, Germany). The post-treatment samples were taken at the same hospital one year after the start of Tysabri treatment. The Tysabri treatment consisted of a year-long treatment of monthly natalizumab infusion (300 mg intravenously, infused over approximately one hour, every four weeks). All patients gave their consent for the repeated CSF sampling. Immediately after sampling, the CSF samples were centrifuged for 10 min at 3000 rpm to discard cells and cellular elements. The samples were subsequently used for routine CSF diagnostics, which included quantification of total protein concentration ( Subsequently the data were exported in Excel format.
The raw abundances of all identified peptides were compared between the groups of samples (before and after treatment with natalizumab) by performing a paired t-test on all individual peptides. Proteins of which 50% or more of the peptides had a low pvalue in this t-test (p<0.01) were deemed to be significantly differentially abundant between the two groups.
Validation by Selected Reaction Monitoring
To validate the found differentially abundant proteins a validation sample set of CSF samples of natalizumab treated patients was collected at the Karolinska Institute in Stockholm, Sweden. The CSF samples, which were taken from 20 patients both before and after treatment were stored at -80°C before shipping on dry ice to the analysis laboratory ( We performed data analysis using the SRM data analysis program Skyline (version 1.1). Concentrations of the analyte peptides were determined based on the ratio between the peak area of the analyte peptide to the peak area of the spiked isotopelabelled internal peptide standard, which was added at a known concentration.
Validation of Chitinase-3-like protein 1 by ELISA To further confirm the differential abundance of chitinase-3-like protein 1 between untreated and natalizumab treated multiple sclerosis patients, an ELISA for this protein was purchased, and performed according to the manufacturers (R&D Systems, Abingdon, United Kingdom) instructions.
Results
Using ESI-Orbitrap mass spectrometry a total of 3289 peptides were identified during the measurements of the "before treatment" and "after treatment" CSF samples of the seventeen relapsing remitting multiple sclerosis patients in the discovery sample set.
These peptides relate to 578 unique proteins, of which 301 were identified by 2 or more peptides. Using a paired t-test to compare the CSF samples from before treatment to the samples from after treatment, 122 peptides had a p-value below 0.01 (statistical background determined by permutation: 33+/-21). For fourteen proteins 50% or more of the peptides had a p-value lower than 0.01, fulfilling the pre-set criterion for differential abundance ( Additionally, an ELISA for chitinase-3-like protein 1 was performed for further confirmation, which showed a significant decrease in abundance of this protein after treatment (p = 0.004) in CSF of MScl patients in the validation sample set ( Figure 2 ).
Discussion
In this study, we analyzed the CSF proteome of MScl patients treated with natalizumab to assess the effects of the drug on the proteins in the CSF by comparing paired samples from patients before treatment and twelve months after treatment. Overall the changes in the CSF proteome after twelve months treatment with natalizumab were limited, but we were able to make a number of interesting observations.
The observation that the proteins related to inflammation are less abundant in CSF after natalizumab treatment is in line with the proposed mechanism of action of the Also in line with the proposed mechanism of natalizumab is the lack of significantly differentially abundant neurodegenerative proteins after treatment. As the drug mechanism firmly points towards an effect on the inflammatory part of the disease processes, an effect on neurodegeneration was not directly expected to be observed here. Although a previous study shows that axonal damage in MScl is reduced by natalizumab treatment, it is anticipated that a highly effective anti-inflammatory treatment reduces axonal loss, as inflammatory activity is associated with axonal damage 17 . Consequently, these neurodegenerative effects are likely secondary to inflammatory processes. In contrast to the study by Ottervald and co-workers, in the presented study CSF samples from 6 months after the start of natalizumab treatment
were not included 10 . The neurodegeneration-related proteins, alpha-1 antichymotrypsin, contactin-1, neuronal cell adhesion molecule and neural cell adhesion molecule 1, which Ottervald et al. described as significantly less abundant after six months of treatment, but not after twelve months treatment, were not significantly differentially abundant after twelve months of natalizumab treatment in our study. Since no CSF samples were taken after six months of natalizumab treatment and analysed in this study, as well as the fact that the experimental procedures differed substantially between the studies, it is difficult to compare them.
Three of the four proteins were even slightly higher abundant after treatment, although these values did not reach significant levels. Hence, no proteins that had previously been related to neurodegenerative effects in MScl could be observed in CSF to be affected by natalizumab treatment in this study.
The majority of differentially abundant proteins found to be less abundant after natalizumab treatment (Table 2) One of the main cell types that secretes this protein are macrophages, linking the protein to the inflammatory response. Increased abundance of this protein in all likelihood is not specific for conversion of CIS to MScl or response to natalizumab treatment in MScl patients, but rather a marker for inflammatory activity in the affected compartment, which is supported by the observation of increased levels in serum of several types of cancers and diseases such as rheumatoid arthritis [20] [21] [22] .
Additionally, the role of the chitinase family in the pathogenesis of MScl is further exemplified by the observation of increased plasma levels of chitotriodase in MScl patients compared to controls [23] [24] .
In conclusion, natalizumab treatment of MScl patients results in a decrease in the levels of inflammation-related proteins in the CSF, which is in line with the proposed mechanism of action of natalizumab. CSF proteins related to neurodegeneration were not affected by natalizumab treatment. A decrease in the CSF levels of chitinase 3-like protein 1, a potential marker for conversion of CIS to clinically definite MScl, was also observed in the patients after twelve months treatment with natalizumab. 
